Table 1.

Individual clinical data of patients with SARS-CoV-2-related thyrotoxicosis prospectively evaluated after recovery of COVID-19

	BASELINE				FOLLOW-UP
Sex	Age (years)	TSH (mU/L)	FT4 (pmol/L)	FT3 (pmol/L)	Duration (days)	TSH (mU/L)	FT4 (pmol/L)	FT3 (pmol/L)	Thyroid volume (mL)	Thyroid hypoecogenicity
M	66	0.33	14.36	4.78	30	1.90	15.00	NA	12	NO
F	58	0.31	19.00	3.70	41	2.25	13.00	4.90	9.5	NO
F	85	0.20	19.00	7.33	43	0.70	10.48	6.00	9	NO
F	55	0.21	17.48	4.95	44	0.55	13.97	5.73	15	NO
F	64	0.30	22.23	5.28	60	3.19	12.50	3.00	10	YES
M	43	0.32	12.53	4.77	60	1.81	11.00	NA	12	NO
M	61	0.17	19.93	5.05	60	1.31	14.00	NA	10	YES
M	53	0.12	16.86	3.86	60	0.57	13.00	NA	14	YES
M	61	0.29	12.00	4.00	62	1.11	9.93	5.16	5	YES
F	60	0.32	18.50	4.82	66	0.70	16.00	NA	11	NO
M	48	0.24	15.68	4.92	70	0.45	11.00	NA	19	NO
M	49	0.12	13.65	4.34	90	6.78	4.11	1.80	6.5	YES
M	81	0.19	27.66	3.49	90	3.77	12.60	NA	21	YES
F	73	0.13	22.44	4.09	90	1.84	12.23	2.68	11.3	NO
M	76	0.20	15.56	4.53	90	1.64	12.87	4.73	14	YES
F	64	0.33	20.75	4.10	90	1.60	14.30	5.00	3.0	NO
M	74	0.33	16.38	5.20	90	1.36	10.62	6.58	50	NO
F	80	0.14	13.59	3.86	90	1.21	15.10	5.00	10.2	YES
F	67	0.29	22.40	4.50	90	0.92	17.00	NA	11	NO
F	74	0.30	18.68	4.50	90	0.86	15.00	4.30	3.2	NO
M	77	0.33	15.82	3.28	90	0.66	13.00	NA	18	NO
M	62	0.30	16.60	4.69	92	2.11	NA	NA	22	YES
M	57	0.14	24.05	4.00	93	1.50	12.28	4.04	9.5	YES
M	70	0.05	30.49	3.50	96	3.44	NA	NA	24	NO
M	68	0.08	18.26	4.74	96	0.93	NA	NA	12	NO
F	77	0.12	26.30	4.30	97	1.49	13.66	2.77	12	NO
M	57	0.20	16.90	4.50	100	0.63	NA	NA	16.5	NO
M	65	0.09	17.59	4.75	120	1.03	NA	NA	16	NO
M	63	0.33	19.00	5.00	120	0.93	16.00	NA	13	NO

F females, FT3 free-iodiothyronine, FT4 free-thyroxine, I increased, M males, NA not available, TSH thyrotropin